All News
What should head-to-head studies in inflammatory arthritis teach us?
The multimillion dollar question for inflammatory arthritis prescriptions is: which drug should I use next?
Read Article
Beyond malignancy, look out for LICATS with CAR-T
CAR T cell therapy took the centre stage in 2022 where data pertaining to a successful case series of 5 patients with refractory SLE were published by Prof Schett’s group. Since then, this area of therapeutic has expanded exponentially. Our growing enthusiasm was slightly dampened though when the FDA required all six approved CAR T-cell therapies in oncology to include a black box warning regarding the risk of second primary malignancies in January 2024. At ACR25, Prof Schett’s group described a new form of toxicity in patients with autoimmune disease receiving CAR T-cell therapy, most likely due to the cleansing of immune cells from the affected organs.
Read Article
The Long View of Diagnostic Delay in Axial Spondyloarthritis
At #ACR25, Abstract #1407 presented a cross-sectional analysis from the Brazilian Spondyloarthritis Registry (RBE), offering a unique perspective on how diagnostic patterns have evolved over six decades. https://t.co/7ttYXJtfpc
Dr. John Cush RheumNow ( View Tweet)
#ACR25 – Day 2 Report
Here are 3 abstracts that caught my eye on Day 2 at #ACR25. Notably these have takeaway messages that should support your current practices.
https://t.co/xKPAgeWudD https://t.co/Fb16l6A252
Links:
Dr. John Cush RheumNow ( View Tweet)
Cellular Biomarkers of Rheumatoid Arthritis
Dr. Jeffrey Sparks reports on four abstracts at #ACR25.
https://t.co/ZO259DXIcW https://t.co/HOpgiXfYvM
Dr. John Cush RheumNow ( View Tweet)
PsA: Impact of Sex
Dr. Arthur Kavanaugh highlights the importance of sex on disease characteristics and response to therapy in psoriatic arthritis, reporting from #ACR25.
https://t.co/QtU4iATexR https://t.co/uCJsxYpFTc
Dr. John Cush RheumNow ( View Tweet)
Nerandomilast for ILD
Dr. Mike Putman reports on abstract 1662 (Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial). #ACR25
https://t.co/J0e4SbVgFE https://t.co/dlOM700yVQ
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Best Abstracts - Day 2
After a full day at the Chicago Convention center the RheumNow faculty have posted some of their favorite reports included these that they labeled as being the "best' of day 2.
https://t.co/gyIWQXVJ50 https://t.co/vjlK41hzFD
Links:
Dr. John Cush RheumNow ( View Tweet)
Are we putting the CAR-T before the horse?
CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure. https://t.co/niPU5cAojP
Dr. John Cush RheumNow ( View Tweet)
Marketscan claims study of 62,813 IMID women w/ 70,529 pregnancies & 69,412 births, 4,485 (7.1%) were exposed to at least one TNFi during pregnancy & 3,559 postpartum. TNFi use NOT assoc w/ SIE risk during Preg (HR 1.39; 0.95-2.05) or postpartum (HR 1.22; https://t.co/NsxOLpT0ds
Dr. John Cush RheumNow ( View Tweet)
💬 #ACR25 Topic Panels — LIVE!
Nov. 5 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology:
👉 SpA
Join Us Live on:
X • Facebook • YouTube • LinkedIn • https://t.co/V10S4oVFsv
Top experts. Real clinical insight. Don't miss these discussions https://t.co/ARrEpN2ybC
Links:
Dr. John Cush RheumNow ( View Tweet)
GLP-1 and SGLT-2: Treatments Too Good to Ignore?
Dr. Peter Nash reviews several studies presented on GLP-1s at #ACR25. He recommends for review abstracts: 0841, 0849, 1027, 2685, 0165, 0233 and 2658.
https://t.co/OclO05bpku https://t.co/kASID9jnAP
Dr. John Cush RheumNow ( View Tweet)
B Cell Depletion: Check the Lymph Node
Dr. Akhil Sood reports on abstract 2695 (B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents) presented at #ACR25.
https://t.co/BjgIC3Kng0 https://t.co/flfyLZYW8q
Dr. John Cush RheumNow ( View Tweet)
🌟 Wonderful news! One of the EMEUNET Top 10 Abstracts ACR 2025 has been accepted on Rheumatology!
🎊 Congratulations Erdem Bektas (@ebektasmd ) for this achievement!
👉You can read the manuscript in this link: https://t.co/teEscaBVG3
#EMEUNET https://t.co/BKRXTXiQ8U
Links:
EMEUNET EMEUNET ( View Tweet)
Join us as we celebrate & congratulate, Eric L. Matteson, MD, MPH, recipient of the 2025 ACR Presidential Gold Medal Award! 🌟 VIEW → https://t.co/ZcIXeZbAKr @MayoClinic #ACR25 https://t.co/7G07K7ZkjS
Links:
American College of Rheumatology ACRheum ( View Tweet)
🆕 Clinical Year in Review at #ACR25
By Dr. Bryant England @UNMC_Rheum
🔶 Review the most impactful studies in #Rheumatology from the past year!
❓ Any studies you would add to the list?
#RheumX #RheumTwitter #ACR2025 https://t.co/rgOb4ZV4r8
Mithu Maheswaranathan, MD MithuRheum ( View Tweet)
This and other reports on palindromic rheumatism show that PR is a pre-clinical RA state, both having same predictive factors for progression to RA! https://t.co/jfpraGfe72
Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis: Which biologic agent is the best first choice?
A growing arsenal of therapeutic targets in psoriatic arthritis (PsA) has enhanced the landscape of treatment in patients with this disease.
https://t.co/pRMyPCvMrN https://t.co/nOgnf5F3Pw
Dr. John Cush RheumNow ( View Tweet)
Should we be using JAKi more in female SpA patients?
In recent years, data has emerged suggesting that female patients with spondyloarthritis, both psoriatic arthritis and axial spondyloarthritis, may have worse outcomes than male patients. A number of post-hoc analyses of https://t.co/smLao0q2hv
Dr. John Cush RheumNow ( View Tweet)
